Table 1.
Baseline characteristics of study participants (effectiveness analysis set)
| Effectiveness analysis set (n = 4032) | |
|---|---|
| Demographic characteristics | |
| Gender (% females) | 71.92% (male 28.03%) |
| Age at initial visit (years, mean ± SD) | 39.1 ± 10.00 |
| Body mass index (kg/m2, mean ± SD) | 25.2 ± 5.24 |
| MS diagnosis and history | |
| MS diagnosis at enrollment | |
| G35.1-0 | 53.03% |
| G35.1-1 | 18.50% |
| G35.1 | 15.10% |
| G35.9 | 9.35% |
| Other categories | < 2% |
| Time between MS diagnosis and start of PANGAEA (years, mean ± SD) | 8.1 ± 6.27 |
| Lesions | |
| Presence of contrast media enhancing lesions | 37.48% |
| Multiple lesions in T2 weighted scan | 74.13% |
| Absence of gadolinium enhancing lesions | 55.26% |
| Disease activity | |
| Relapses per patient during the last 12 months (mean ± SD) | 1.5 ± 1.15 |
| EDSS | |
| ≤ 1.5 | 22.99% |
| > 1.5 to ≤ 2.5 | 21.70% |
| > 2.5 to ≤ 3.5 | 13.74% |
| > 3.5 to ≤ 4.5 | 19.98% |
| > 4.5 | 13.71% |
| Not performed | 0.6% |
| Missing | 7.37% |
| Concomitant diseases | |
| Any concomitant disease | 32.19% |
| Most commonly documented concomitant diseases | |
| Depression | 6.17% (n = 249) |
| Hypertension | 6.96% (n = 281) |
| Migraine | 2.3% (n = 93) |
| Hypothyroidism | 2.13% (n = 86) |
| Concomitant treatment | |
| Any concomitant non-MS treatment | 41.39% |
| Any concomitant MS treatment | 55.23% |
G35.1-0 relapsing remitting MS without mentioning of an acute exacerbation or progression, G35.1-1 relapsing remitting MS with mentioning of an acute exacerbation or progression, G35.1 RRMS, G35.9 MS not otherwise specified, EDSS Expanded Disability Status Scale